false000001427200000142722020-02-202020-02-200000014272us-gaap:CommonStockMember2020-02-202020-02-200000014272bmy:One000NotesDue2025Member2020-02-202020-02-200000014272bmy:CelgeneContingentValueRightsMember2020-02-202020-02-200000014272bmy:BristolMyersSquibbContingentValueRightsMember2020-02-202020-02-200000014272bmy:One750NotesDue2035Member2020-02-202020-02-20 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

  FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 20, 2020 

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)  

  [DATA_TABLE_REMOVED] 

430 East 29th Street, 14th Floor 

New York, NY, 10016 

(Address of Principal Executive Office) 

Registrant’s telephone number, including area code: (212) 546-4000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

 ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)      

 ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)      

 ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))      

 ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))      

 Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.      

(b) On February 20, 2020, Mr. Michael Grobstein and Mr. Alan Lacy notified Bristol-Myers Squibb Company that they will not stand for re-election to the Board of Directors at the 2020 Annual Meeting of Shareholders. The Board also set the number of directors at twelve effective as of the 2020 Annual Meeting of Shareholders, which is expected to be held on May 5, 2020. 

 Item 9.01.  Financial Statements and Exhibits.      

    (d)   Exhibits     

The following exhibit is included as part of this Current Report on Form 8-K: 

Exhibit 

No.      

Description    

    104     The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).    

- 2 - 

EXHIBIT INDEX 

Exhibit 

No.      

Description    

  104     The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).    

- 3 - 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

 - 4 -